TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03134027

Intervention type: PROCEDURE
Intervention: Bone marrow biopsy
Description: Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
Study: NCT03233906

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chia Seeds- Salvia Hispanica
Description: Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
Study: NCT02529618

Intervention type: DEVICE
Intervention: integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)
Description: iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.

Intervention type: DEVICE
Intervention: integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)
Description: iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.

Intervention type: DEVICE
Intervention: Riddell High Impact Technology (HIT) System
Description: The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
Study: NCT01972685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transbronchial Biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VATS biopsy
Study: NCT03930875

Intervention type: OTHER
Intervention: Aspirin Resistance testing
Description: Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)

Intervention type: OTHER
Intervention: Aspirin Resistance testing
Description: Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
Study: NCT01985035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Reduction of energy intake in order to weight loss
Study: NCT03930875

Intervention type: OTHER
Intervention: Aspirin Resistance testing
Description: Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
Study: NCT04395924

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta
Description: During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)
Study: NCT03164031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close-fitting orthotic shorts
Description: The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Looser fitting shorts
Description: Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
Study: NCT02987166

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Conformal Radiation Therapy
Description: 24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Conformal Radiation Therapy
Description: 24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Conformal Radiation Therapy
Description: 24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg
Study: NCT02529618

Intervention type: DEVICE
Intervention: i1 Biometrics Vector Mouth Guard
Description: The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
Study: NCT03529162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long head of Biceps Tenodesis
Description: Patients will be randomized into two different groups to compare biceps tenodesis techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long head of Biceps Tenodesis
Description: Patients will be randomized into two different groups to compare biceps tenodesis techniques
Study: NCT04778215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A progressive specific lumbar stabilization program
Description: The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
Study: NCT04383041

Intervention type: OTHER
Intervention: No intervention
Description: Completing questionnaires via ePRO app from their own mobile devices
Study: NCT02212249

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: soluble Ve cadherin
Description: dosage of soluble VE cadherine in each arms

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: soluble Ve cadherin
Description: dosage of soluble VE cadherine in each arms
Study: NCT00918905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitor
Description: Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day.
Study: NCT03807258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Evaluations by TMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: Evaluations by TMS
Study: NCT02645435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip replacement
Description: Total hip replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip replacement
Description: Total hip replacement
Study: NCT05736003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Removal of gallbladder laparoscopically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Removal of gallbladder laparoscopically
Study: NCT04380480

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy
Description: One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56.
Study: NCT01378156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS7 plasmid DNA and MVA62B vaccine
Description: JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
Study: NCT03044730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01785940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene block
Description: Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
Study: NCT03389594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical guide
Description: Surgical Guide for this group will designed from 0.4mm voxel size
Study: NCT01115114

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU
Description: A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IMBED
Description: After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Liaison
Description: Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
Study: NCT02296528

Intervention type: DEVICE
Group type: OTHER
Intervention: Swallowing Expansion Device
Description: SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates.
Study: NCT01627379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, 5-FU
Description: Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled.
Study: NCT01574118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revisiting the Trauma memories
Description: Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Revisiting the Trauma memories
Description: Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing the trauma memories
Description: The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Processing the trauma memories
Description: The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Memory Retrieval Trial
Description: Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to video clips related to the patient's trauma
Description: Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing retraining
Description: Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Homework
Description: Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
Study: NCT03395561

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green coffee
Description: 2 capsuls

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study: NCT01574118

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Homework
Description: Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compound extinction
Description: The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
Study: NCT02558595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill that matches niacinamide pill is size, shape and color
Study: NCT02415582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercises
Description: Combined resistance and aerobic exercise

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 45 minutes resting sitting
Study: NCT00443794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazides
Description: Capsule (blinded) oral administration once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril with Thiazide
Description: Capsule (blinded) oral administration 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide plus atenolol
Description: Caspule (blinded) for oral administration once daily for 12 weeks
Study: NCT00964301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Education
Description: Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
Study: NCT00443794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril plus atenolol
Description: Capsule ( blinded) for oral administration once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril plus atenolol plus thiazide
Description: Capsule (blinded) for oral administration once daily for 12 weeeks